Our experts compare the public comment letter files for the GUARD and GLOBE models.
Executive takeaway
The public comment files reflect different policy fault lines for the two proposed demonstration models. GUARD generated a legal and industry-centered backlash tied to Part D structure and innovation concerns. Whereas GLOBE generated a broader operational and patient-access response centered on Part B care delivery, buy-and-bill viability, and continuity of care.
Background
CMS proposed GUARD as a five-year model for Medicare Part D with a planned January 1, 2027 launch date and comments due February 23, 2026. GLOBE was proposed as a five-year model for clinician-administered drugs with a planned October 1, 2026 launch date and the same February 23, 2026 comment deadline. Both models rely on geographic selection and international benchmarking logic, but the comments show a different pattern of objections and potential requested modifications.
This analysis summarizes themes in public comment letters and does not take a position on whether CMS should finalize either model.
How stakeholder comments differ at a glance
| Measure | GUARD | GLOBE | What it suggests |
| Number of letters | 159 | 151 | Comparable interest in both demonstration models |
| Largest sender bloc | Pharma / biotech industry (53) | Pharma / biotech industry (69) | Industry is the largest stakeholder group for both programs |
| Second-largest bloc | Patient access / advocacy (38) | Patient access / advocacy (37) | Patient-oriented organizations are both central stakeholders for both programs |
| Operational bloc | Provider / pharmacy / distribution (20) | Provider / pharmacy / distribution (21) | Operational stakeholders matter in both but represent a larger proportion in GLOBE. |
| Overall tenor | More heavily negative | More mixed / neutral | GLOBE has a larger middle category and more conditional-support letters. |
Sender mix
| Sender bucket | GUARD | GLOBE |
| Pharma / biotech industry | 53 | 69 |
| Patient access / advocacy | 38 | 37 |
| Provider / pharmacy / distribution | 20 | 21 |
| Public policy / think tank / academic | 26 | 13 |
| All others | 18 | 11 |
The sender composition tells part of the story. GLOBE drew a larger absolute response from industry, but it also activated a provider- and distribution-focused implementation conversation more clearly than GUARD. By contrast, GUARD produced a larger policy and academic discussion around the overall design and legal basis of the model.
Tone and posture
The most important tonal difference is that GUARD was read by many commenters as a direct challenge to the statutory and economic architecture of Part D, whereas GLOBE was more often read as a potentially workable idea whose proposed implementation could destabilize care delivery. Put differently, the GUARD comments read more like a brief against the model; the GLOBE comments read more like a warning that the model cannot be implemented as proposed.
- GUARD produced stronger and more consistent legal-authority arguments, especially from industry and manufacturer-aligned stakeholders.
- GLOBE produced more neutral or conditionally supportive letters, especially from provider, pharmacy, and some patient-facing groups that accepted the affordability objective but objected to the delivery consequences.
- The very small, clearly positive letters exist for both programs, but they appear more credible and more visible in GLOBE than in GUARD.
The substantive split: Part D structure versus Part B delivery
The clearest difference between the comment letters is where the model interacts with the healthcare system. GUARD triggered concern about Part D pricing architecture, statutory authority, manufacturer liability, and downstream effects on innovation. GLOBE triggered concern about what happens when a global benchmark is layered onto provider-administered drugs: reimbursement timing, practice economics, inventory risk, specialty distribution, white bagging, and continuity of care.
Direct beneficiary out-of-pocket relief is a real contrast point
One of the clearest policy differences between the two models is that GLOBE was widely understood to offer at least the possibility of direct beneficiary out-of-pocket relief, because patient coinsurance would be tied to the lower GLOBE benchmark when applicable. Several commenters treated that feature as a meaningful design virtue even when they opposed other parts of the model.
By contrast, GUARD was repeatedly criticized for generating savings for the federal government without guaranteeing corresponding point-of-sale or cost-sharing relief for Medicare Part D beneficiaries. Some GUARD commenters explicitly used GLOBE as the comparison point and argued that GUARD should be redesigned so that patients, rather than only the government, share directly in any savings.
| Dimension | GUARD comments | GLOBE comments |
| Primary program setting | Part D | Part B / clinician-administered drugs |
| Most visible legal question | Scope of CMMI authority and whether GUARD is a bona fide test | Still present, but less dominant than practical delivery concerns |
| Core economic concern | Reduced manufacturer revenues and downstream impact on innovation | Provider reimbursement stability, acquisition-cost mismatch, and downstream access effects |
| Operational center of gravity | Manufacturer rebates, Part D mechanics, beneficiary geography, and program overlap | Buy-and-bill, white bagging, site-of-care shifts, specialty distribution, and care continuity |
| Typical patient-facing concern | Future innovation, fewer therapies, especially in rare disease | Near-term treatment disruption and access to physician-administered therapies |
Rare disease and innovation
Rare-disease arguments were a consistent feature in both sets of letters, but they operate somewhat differently. In GUARD, these objections often connect global benchmarking to a longer-term innovation story: fewer expected returns, weaker investment incentives, and fewer future therapies for populations with limited treatment options. In GLOBE, rare-disease arguments remain present, but they are more closely tied to treatment continuity, limited substitutes, medically fragile patients, and the practical consequences of disrupting delivery channels for infused or administered therapies.
Why buy-and-bill matters so much in GLOBE
Buy-and-bill concerns are one of the strongest reasons the GLOBE record deserves separate treatment. The argument is not merely that practices prefer larger margins. It is that a benchmark-driven drop or lag in reimbursement relative to acquisition cost could leave practices underwater, which in turn can reduce willingness to stock drugs, push care into hospital outpatient departments, increase white bagging, and create delays or disruptions for patients. This is a care-delivery critique, not just a pricing complaint.
What the comparison implies
Stakeholder resistance changes shape depending on whether a model is experienced primarily as a pricing reform or a care-delivery reform.
- GUARD appears to have encountered a more ideological and legal backlash while GLOBE encountered more operational and clinical concerns.
- Revisions to the models to address the concerns would need both a narrower legal theory and a more credible implementation plan for provider- and patient-facing consequences.
- Across both models, commenters repeatedly ask CMS to narrow the scope of exposure for orphan and rare-disease products, add better patient safeguards, and reduce operational ambiguity before launch.
Although legal authority arguments were less prominent in the GLOBE file, statutory authority remains a key issue for both models.
To discuss the implications of these models on your pricing and market access strategy, reach out to our experts.
